
- /
- Supported exchanges
- / US
- / PHMMF.PINK
Pharma Mar SAU (PHMMF PINK) stock market data APIs
Pharma Mar SAU Financial Data Overview
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pharma Mar SAU data using free add-ons & libraries
Get Pharma Mar SAU Fundamental Data
Pharma Mar SAU Fundamental data includes:
- Net Revenue: 176 M
- EBITDA: 11 726 K
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-21
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharma Mar SAU News

High Growth Tech Stocks To Watch In July 2025
As of early July 2025, global markets are experiencing a notable upswing, with major U.S. indices like the S&P 500 and Nasdaq Composite reaching record highs for the second consecutive week, driven by...


3 Global Growth Companies Insiders Own With Up To 93% Earnings Growth
As global markets continue to navigate a complex landscape marked by record highs in major U.S. indices and fluctuating economic indicators, investors are keenly observing growth opportunities that al...

High Growth Tech Stocks in Europe with Promising Potential
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining relatively flat and major indexes like France's CAC 40 and Italy’s FTSE MIB posting m...

European Growth Stocks With High Insider Ownership July 2025
As of July 2025, the European stock market has shown mixed performance, with the pan-European STOXX Europe 600 Index remaining relatively flat and major indexes like France's CAC 40 and Italy's FTSE M...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.